Merda Biopharma
META Pharmaceuticals Inc. (默达生物) is a pioneering Chinese biopharmaceutical company specializing in the development of first-in-class original small molecule drugs targeting immune metabolism for autoimmune and metabolic diseases. Founded in 2021 by a team from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center, the company leverages cutting-edge biological theories and AI-driven drug discovery in partnership with XtalPi to develop safer, more effective treatments. Their lead candidate, META-001-PH, is a breakthrough small molecule for primary hyperoxaluria, having received FDA orphan drug and rare pediatric disease designations, with clinical trials planned for 2025. META Pharmaceuticals aims to address large global markets with unmet needs, including autoimmune diseases and rare metabolic disorders, and has received multiple industry recognitions and strategic investments. The company is positioned as a leader in immune metabolism therapeutics in China and Asia, advancing innovative therapies with strong IP and clinical development pipelines.
Merda Biopharma
META Pharmaceuticals Inc. (默达生物) is a pioneering Chinese biopharmaceutical company specializing in the development of first-in-class original small molecule drugs targeting immune metabolism for autoimmune and metabolic diseases. Founded in 2021 by a team from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center, the company leverages cutting-edge biological theories and AI-driven drug discovery in partnership with XtalPi to develop safer, more effective treatments. Their lead candidate, META-001-PH, is a breakthrough small molecule for primary hyperoxaluria, having received FDA orphan drug and rare pediatric disease designations, with clinical trials planned for 2025. META Pharmaceuticals aims to address large global markets with unmet needs, including autoimmune diseases and rare metabolic disorders, and has received multiple industry recognitions and strategic investments. The company is positioned as a leader in immune metabolism therapeutics in China and Asia, advancing innovative therapies with strong IP and clinical development pipelines.